Cargando…

Molecular mechanisms of Huanglian Jiedu decoction in treating Alzheimer’s disease by regulating microbiome via network pharmacology and molecular docking analysis

BACKGROUND: Huanglian Jiedu decoction (HLJDD) is a famous traditional Chinese medicine prescription, which is widely used in the treatment of Alzheimer’s disease (AD). However, the interaction between bioactive substances in HLJDD and AD-related targets has not been well elucidated. AIM: A network p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Renyuan, Shi, Shenggan, Zhang, Qin, Yuan, Shuqin, Guo, Tong, Guo, Jinlin, Jiang, Peidu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060893/
https://www.ncbi.nlm.nih.gov/pubmed/37009506
http://dx.doi.org/10.3389/fcimb.2023.1140945
_version_ 1785017178247921664
author Zheng, Renyuan
Shi, Shenggan
Zhang, Qin
Yuan, Shuqin
Guo, Tong
Guo, Jinlin
Jiang, Peidu
author_facet Zheng, Renyuan
Shi, Shenggan
Zhang, Qin
Yuan, Shuqin
Guo, Tong
Guo, Jinlin
Jiang, Peidu
author_sort Zheng, Renyuan
collection PubMed
description BACKGROUND: Huanglian Jiedu decoction (HLJDD) is a famous traditional Chinese medicine prescription, which is widely used in the treatment of Alzheimer’s disease (AD). However, the interaction between bioactive substances in HLJDD and AD-related targets has not been well elucidated. AIM: A network pharmacology-based approach combined with molecular docking was performed to determine the bioactives, key targets, and potential pharmacological mechanism of HLJDD against AD, through the regulation of microbial flora. MATERIALS AND METHODS: Bioactives and potential targets of HLJDD, as well as AD-related targets, were retrieved from Traditional Chinese Medicine Systems Pharmacology Analysis Database (TCMSP). Key bioactive components, potential targets, and signaling pathways were obtained through bioinformatics analysis, including protein-protein interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Subsequently, molecular docking was performed to predict the binding of active compounds with core targets. RESULTS: 102 bioactive ingredients of HLJDD and 76 HLJDD-AD-related targets were screened. Bioinformatics analysis revealed that kaempferol, wogonin, beta-sitosterol, baicalein, acacetin, isocorypalmine, (S)-canadine, (R)-canadine may be potential candidate agents. AKT1, TNF, TP53, VEGFA, FOS, PTGS2, MMP9 and CASP3 could become potential therapeutic targets. 15 important signaling pathways including the cancer pathway, VEGF signaling pathway, and NF-κB signaling pathway might play an important role in HLJDD against AD. Moreover, molecular docking analysis suggested that kaempferol, wogonin, beta-sitosterol, baicalein, acacetin, isocorypalmine, (S)-canadine, and (R)-canadine combined well with AKT1, TNF, TP53, VEGFA, FOS, PTGS2, MMP9, CASP3, respectively. CONCLUSION: Our results comprehensively illustrated the bioactives, potential targets, and possible molecular mechanisms of HLJDD against AD. HLJDD may regulate the microbiota flora homeostasis to treat AD through multiple targets and multiple pathways. It also provided a promising strategy for the use of traditional Chinese medicine in treating human diseases.
format Online
Article
Text
id pubmed-10060893
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100608932023-03-31 Molecular mechanisms of Huanglian Jiedu decoction in treating Alzheimer’s disease by regulating microbiome via network pharmacology and molecular docking analysis Zheng, Renyuan Shi, Shenggan Zhang, Qin Yuan, Shuqin Guo, Tong Guo, Jinlin Jiang, Peidu Front Cell Infect Microbiol Cellular and Infection Microbiology BACKGROUND: Huanglian Jiedu decoction (HLJDD) is a famous traditional Chinese medicine prescription, which is widely used in the treatment of Alzheimer’s disease (AD). However, the interaction between bioactive substances in HLJDD and AD-related targets has not been well elucidated. AIM: A network pharmacology-based approach combined with molecular docking was performed to determine the bioactives, key targets, and potential pharmacological mechanism of HLJDD against AD, through the regulation of microbial flora. MATERIALS AND METHODS: Bioactives and potential targets of HLJDD, as well as AD-related targets, were retrieved from Traditional Chinese Medicine Systems Pharmacology Analysis Database (TCMSP). Key bioactive components, potential targets, and signaling pathways were obtained through bioinformatics analysis, including protein-protein interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Subsequently, molecular docking was performed to predict the binding of active compounds with core targets. RESULTS: 102 bioactive ingredients of HLJDD and 76 HLJDD-AD-related targets were screened. Bioinformatics analysis revealed that kaempferol, wogonin, beta-sitosterol, baicalein, acacetin, isocorypalmine, (S)-canadine, (R)-canadine may be potential candidate agents. AKT1, TNF, TP53, VEGFA, FOS, PTGS2, MMP9 and CASP3 could become potential therapeutic targets. 15 important signaling pathways including the cancer pathway, VEGF signaling pathway, and NF-κB signaling pathway might play an important role in HLJDD against AD. Moreover, molecular docking analysis suggested that kaempferol, wogonin, beta-sitosterol, baicalein, acacetin, isocorypalmine, (S)-canadine, and (R)-canadine combined well with AKT1, TNF, TP53, VEGFA, FOS, PTGS2, MMP9, CASP3, respectively. CONCLUSION: Our results comprehensively illustrated the bioactives, potential targets, and possible molecular mechanisms of HLJDD against AD. HLJDD may regulate the microbiota flora homeostasis to treat AD through multiple targets and multiple pathways. It also provided a promising strategy for the use of traditional Chinese medicine in treating human diseases. Frontiers Media S.A. 2023-03-16 /pmc/articles/PMC10060893/ /pubmed/37009506 http://dx.doi.org/10.3389/fcimb.2023.1140945 Text en Copyright © 2023 Zheng, Shi, Zhang, Yuan, Guo, Guo and Jiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Zheng, Renyuan
Shi, Shenggan
Zhang, Qin
Yuan, Shuqin
Guo, Tong
Guo, Jinlin
Jiang, Peidu
Molecular mechanisms of Huanglian Jiedu decoction in treating Alzheimer’s disease by regulating microbiome via network pharmacology and molecular docking analysis
title Molecular mechanisms of Huanglian Jiedu decoction in treating Alzheimer’s disease by regulating microbiome via network pharmacology and molecular docking analysis
title_full Molecular mechanisms of Huanglian Jiedu decoction in treating Alzheimer’s disease by regulating microbiome via network pharmacology and molecular docking analysis
title_fullStr Molecular mechanisms of Huanglian Jiedu decoction in treating Alzheimer’s disease by regulating microbiome via network pharmacology and molecular docking analysis
title_full_unstemmed Molecular mechanisms of Huanglian Jiedu decoction in treating Alzheimer’s disease by regulating microbiome via network pharmacology and molecular docking analysis
title_short Molecular mechanisms of Huanglian Jiedu decoction in treating Alzheimer’s disease by regulating microbiome via network pharmacology and molecular docking analysis
title_sort molecular mechanisms of huanglian jiedu decoction in treating alzheimer’s disease by regulating microbiome via network pharmacology and molecular docking analysis
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060893/
https://www.ncbi.nlm.nih.gov/pubmed/37009506
http://dx.doi.org/10.3389/fcimb.2023.1140945
work_keys_str_mv AT zhengrenyuan molecularmechanismsofhuanglianjiedudecoctionintreatingalzheimersdiseasebyregulatingmicrobiomevianetworkpharmacologyandmoleculardockinganalysis
AT shishenggan molecularmechanismsofhuanglianjiedudecoctionintreatingalzheimersdiseasebyregulatingmicrobiomevianetworkpharmacologyandmoleculardockinganalysis
AT zhangqin molecularmechanismsofhuanglianjiedudecoctionintreatingalzheimersdiseasebyregulatingmicrobiomevianetworkpharmacologyandmoleculardockinganalysis
AT yuanshuqin molecularmechanismsofhuanglianjiedudecoctionintreatingalzheimersdiseasebyregulatingmicrobiomevianetworkpharmacologyandmoleculardockinganalysis
AT guotong molecularmechanismsofhuanglianjiedudecoctionintreatingalzheimersdiseasebyregulatingmicrobiomevianetworkpharmacologyandmoleculardockinganalysis
AT guojinlin molecularmechanismsofhuanglianjiedudecoctionintreatingalzheimersdiseasebyregulatingmicrobiomevianetworkpharmacologyandmoleculardockinganalysis
AT jiangpeidu molecularmechanismsofhuanglianjiedudecoctionintreatingalzheimersdiseasebyregulatingmicrobiomevianetworkpharmacologyandmoleculardockinganalysis